Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial

Systolic Blood Pressure Intervention Trial(SPRINT) was an open-label, multicentre, randomized controlled trial. Participants were adults 50 years or older with systolic blood pressure higher than 130 mm Hg. After a median follow-up of 4 years, there was no between-group difference. An intensive treatment to lower systolic blood pressure did not result in a clinically relevant difference compared with standard treatment.

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Time to onset of disability progression was confirmed with four measures and time to requiring a wheelchair was also analyzed. At the study end, the percentage change from baseline was lower in those who initiated oc Relzumab early than in those initially receiving placebo. But progression remains an important unmet need in multiple sclerosis.

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Biotin (MD1003) might enhance neuronal and oligodendrocyte energetics, resulting in improved cell function, repair, or survival. MS-SPI randomised, double-blind, placebo-controlled study found that MD1003 improved disability outcomes over 12 months in patients with progressive multiple sclerosis. The study was done at 90 academic and community multiple sclerosis clinics across 13 countries. 39 (12%) of 326 patients in the MD1003 group compared with 29 (9%) of 316 in the placebo group improved.

Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial

Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis. Authors: The study did not provide evidence to support the use of these drugs for multiple sclerosis fatigue.

Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

The genetic basis of variation in the progression of primary tauopathies has not been determined. We aimed to identify genetic determinants of survival in progressive supranuclear palsy (PSP) In stage one of a two-stage genome-wide association study (GWAS). Genome-wide significant association with survival at chromosome 12 was found. LRRK2 has been associated with sporadic and familial forms of Parkinson's disease. The mechanism of this association might be through a lncRNA-regulated effect on L

Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis

There has been no systematic analysis of a stenosis-risk association in cohort studies. The 5-year ipsilateral stroke risk increased with the degree of asymptomatic carotid stenosis. The benefit of endarterectomy might be underestimated in patients with severe stenosis, we found. Conversely, the 5- year stroke risk was low for patients with moderate stenosis on contemporary medical treatment, calling into question any benefit from revascularization. We conclude that the risk of stroke is highly

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma. 185 patients were randomly assigned to ivosidenib (AG-120) or placebo. Median follow-up for progression-free survival was 6·9 months. Progression- free survival was significantly improved with ivosidenib compared with placebo. Serious adverse events were reported in 36 (30%) of 121 patients receiving ivosidanib and 13 (22%) of 59 patients receiving placebo.

Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer - a randomized study

The efficacy of different timings of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in controlling malignant ascites caused by colorectal cancer is not well defined. The patients were randomized to: CRS, followed by HIPEC and ultrasound-guided HIPEC. The endpoints were complete remission rate of ascites, successful complete CRS rate, and overall survival. CRS+HIPEC and HIPEC+dCRS have the same efficacy in controlling malignant ascites caused by CRC and periton

Departments

Recent Posts